Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Bradley A. McGregor, MD
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04413123CT.gov Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC | — | Active Not Recruiting | — | — | — |
NCT03866382CT.gov Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | — | Recruiting | — | — | — |
NCT03635892CT.gov A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma | — | Active Not Recruiting | — | — | — |
NCT03354884CT.gov caBozantinib in cOllectiNg ductS Renal Cell cArcInoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Collecting Duct Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cabozantinib (this asset) | Bradley A. McGregor, MD | P2 | B · 57 |
| Axitinib | Peking University Cancer Hospital & Institute | P2 | CCC |
| Pamiparib | Jonsson Comprehensive Cancer Center | P2 | CCC |
| Pembrolizumab | Giuseppe Procopio | P2 | CCC |
| Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4) | Giuseppe Procopio | P2 | CCC |
| Nivolumab | Bradley A. McGregor, MD | P2 | CCC |
| Ipilimumab | Bradley A. McGregor, MD | P2 | CCC |
| Pazopanib | Mayo Clinic | P2 | NR |
Other indications for Cabozantinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Carcinoma | — | P4 | BB · 70 |
| Castration-Resistant Prostate Carcinoma | — | P3 | BB · 70 |
| Kidney Cancer | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- AxitinibPeking University Cancer Hospital & InstituteCCC
- PamiparibJonsson Comprehensive Cancer CenterCCC
- PembrolizumabGiuseppe ProcopioCCC
- Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4)Giuseppe ProcopioCCC
- NivolumabBradley A. McGregor, MDCCC
Citation
Floatz Terminal. Cabozantinib in Collecting Duct Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cabozantinib-collecting-duct-carcinoma-118119
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →